NewsRoom Articles - Page 28 of 251

WednesdayNov 02, 2022 9:00 am

Lexaria Bioscience Corp. (NASDAQ: LEXX) Maintains Late 2022/Early 2023 for Full IND Application for DehydraTECH-CBD

Lexaria, through its patented DehydraTECH(TM) technology, is improving the bioavailability of pharmaceuticals and therapeutics (in part) by bypassing first-pass-liver processing, thereby achieving an improved speed of onset, and brain absorption of APIs Hypertension currently affects nearly 50% of all American adults, with the American Heart Association describing it as a “silent killer”, and is now being studied for its effects during pregnancy The company has received positive feedback for its pre-Investigational New Drug meeting from the FDA and has reported that it remains on track to file its full IND application by late 2022/early 2023 It looks to capitalize on…

TuesdayNov 01, 2022 12:00 pm

Tampa Alternative Products Expo To Offer A Festive Vibe Amongst Business Networking

Exhibitors, speakers, businesses, CBD and alternative products vendors, and researchers, are all invited to attend the Tampa Alternative Products Expo 2022 at the Tampa Convention Center. With over 10,000 attendees, 300+ vendors, and 20+ speakers per event, the Expo will exude a festival-like vibe for Tampa's CBD, cannabis, and vape communities. The event is organized by ZJ Events, with a reputation for managing the nation's largest CBD & Hemp Summits. The Alt Pro Expo team has expanded into the alternative products sector, which is currently disrupting traditional markets. This product category includes kratom, nootropics, vapes & nicotine replacements, energy beverages,…

TuesdayNov 01, 2022 9:00 am

Flora Growth Corp. (NASDAQ: FLGC) Focusing on Execution and Brand Integration Following Successful Period of Strategic Investment

Flora Growth recently participated in an earnings call in which the management team discussed the company’s financials as well as its growth strategy and outlook for the remainder of fiscal 2022 as well as 2023 The company noted it had exited a period of investment and is now focusing on execution The period of investment saw the company acquire synergistic brands that, collectively, create a direct-to-consumer house of brands, enabling the company to enter nearly any target market regardless of the legal status of cannabis The company also invested in the infrastructure necessary for the activation of its cultivation facility…

MondayOct 31, 2022 9:00 am

Lexaria Bioscience Corp. (NASDAQ: LEXX) Moves to Address Adverse Effects of Hypertension with DehydraTECH(TM) – CBD

Lexaria is a drug delivery technology company developing DehydraTECH-CBD as a prospective registered treatment for hypertension and potentially other disease states beyond hypertension The company has undertaken multiple de-risking hypertension studies that have not only evidenced that DehydraTECH-CBD is safe and well tolerated, but have also shown that it reduces blood pressure and arterial stiffness Hypertension is a leading contributor to deaths in the United States, damaging organs such as the heart, brain, and kidneys, yet only a tiny proportion of patients have it under control Hypertension, an area of interest and focus for drug delivery technology company Lexaria Bioscience…

WednesdayOct 26, 2022 9:00 am

Advanced Container Technologies Inc. (ACTX) Offers Growing Solution in Industry Seeing Key Government Support

California governor signs 10 cannabis-related bills into law Bills intended to “strengthen California’s cannabis laws, expand the legal cannabis market and redress the harms of cannabis prohibition” ACTX’s Grow Pods offer unmatched control, are capturing a great deal of attention in the cannabis and hemp space As California Gavin Newsom signed 10 cannabis-related legislative bills into law — all in one day (https://cnw.fm/5DJ1m) — companies operating in the cannabis space, including Advanced Container Technologies (OTC: ACTX), look forward to the impact this government support may have on their success. The governor signed bills designed to expand the legal cannabis market…

TuesdayOct 25, 2022 9:45 am

Lexaria Bioscience Corp.’s (NASDAQ: LEXX) Potential Hypertension Medication Poised to Reduce Risk of Blood-Pressure-Induced Dementia, Cognitive Decline

Lexaria Bioscience is a global innovator in drug delivery platforms that has developed the patented DehydraTECH(TM) technology for improved delivery of bioactive compounds The company is currently evaluating DehydraTECH-processed CBD as a potential treatment for high blood pressure Long-term studies have shown that high blood pressure can increase the risk of developing dementia in later life Experts, however, believe that hypertension medication could slow the pace of the cognitive decline In addition to helping hypertension patients keep their condition under control, Lexaria’s DehydraTECH-CBD, which has so far been shown to be safe and well tolerated, could potentially help reduce the…

MondayOct 24, 2022 9:00 am

Advanced Container Technologies Inc. (ACTX) Leaders Talk Game-Changing Microfarm Growing Option on Episode of Leading Podcast

ACTX CEO Doug Heldoorn, Grow Pod inventor Shannon Illingworth discuss the innovative microfarm option on recent Gamechangers LIVE podcast Discussion focuses on history of company, significant health and safety benefits of Grow Pods Company is dedicated to developing, manufacturing and selling advanced cultivation equipment and packaging systems Advanced Container Technologies (OTC: ACTX) chair and CEO Doug Heldoorn was a featured guest on a recent episode of the Gamechangers LIVE podcast (https://cnw.fm/3xv5t). Heldoorn was joined by Shannon Illingworth, inventor of Grow Pods, the microfarm containers that ACTX distributes throughout the United States. During the podcast, the two men discussed the origins…

WednesdayOct 19, 2022 11:15 am

Lexaria Bioscience Corp. (NASDAQ: LEXX) Using Novel DehydraTECH(TM) Technology to Address Unmet Antihypertension Drug Market

Research has shown that co-occurring conditions may be linked to high blood pressure, including bone aging and mental illness The antihypertension drug market is anticipated to rise due to the launch of novel pharmaceuticals and diagnostic agents Valued at US $30.2 billion in 2021, the market is expected to grow at a CAGR of 3%, resulting in a value of US $40 billion by 2031 Lexaria’s patented DehydraTECH(TM) technology offers higher bioavailability of active pharmaceutical ingredients due to, in part, bypassing first-pass-liver processing, improving the speed of onset, and brain absorption The American Heart Association (“AMA”) refers to high blood…

WednesdayOct 19, 2022 9:00 am

Flora Growth Corp. (NASDAQ: FLGC) Building Portfolio of Brands that Resonates with End Consumers as It Targets Margins and Profitability

Flora Growth is a global cannabis company building a connected, design-led collective of plant-based wellness and lifestyle brands The company’s portfolio of brands is designed to deliver the most compelling customer experiences in the world Through its M&A strategy, Flora Growth has brought on board brands like JustCBD, Vessel Brands Inc., Masaya, No Cap Hemp Co., and Mambe Flora hopes to establish meaningful connections with consumers through these brands, which will enable it to increase its margins and profitability The cannabis industry has gone global, undergoing a sea change in commercialization, normalization, and liberalization. According to a report by New…

MondayOct 17, 2022 9:45 am

Lexaria Bioscience Corp.’s (NASDAQ: LEXX) Drug Development Program Seeking to Provide Safe, Well-Tolerated, Effective Antihypertensive Medication Amid Continued Reports of Suboptimal Adherence to Existing Treatments

Lexaria Bioscience, a global innovator in drug delivery technology, has developed a potential treatment for hypertension using the company’s patented DehydraTECH(TM) platform, now shown in several human studies to reduce blood pressure and arterial stiffness Lexaria’s antihypertensive drug development program comes at a time when researchers are documenting poor control of hypertension among both men and women, partly due to suboptimal adherence to existing antihypertension medication Reasons advanced for the suboptimal adherence include lack of awareness or treatment, increased number of prescribed medications, and major adverse effects of the prescribed drugs Lexaria has so far shown that its DehydraTECH-CBD is…

News and publishing service for hemp related companies

Contact us: 512.354.7000